 Christopher Porter
Concepts (375)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Germ-Line Mutation | 8 | 2022 | 172 | 2.310 |
Why?
| | Leukemia | 7 | 2025 | 240 | 2.200 |
Why?
| | Proto-Oncogene Proteins c-ets | 5 | 2022 | 56 | 2.130 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 8 | 2023 | 289 | 1.920 |
Why?
| | Hematologic Neoplasms | 3 | 2024 | 156 | 1.660 |
Why?
| | Neoplastic Syndromes, Hereditary | 4 | 2024 | 44 | 1.550 |
Why?
| | Leukemia, Myeloid, Acute | 9 | 2023 | 630 | 1.550 |
Why?
| | Pyrimidines | 6 | 2017 | 470 | 1.550 |
Why?
| | Interleukin-12 | 3 | 2022 | 121 | 1.500 |
Why?
| | Genetic Predisposition to Disease | 13 | 2025 | 2426 | 1.470 |
Why?
| | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2023 | 80 | 1.340 |
Why?
| | Pyrazoles | 4 | 2017 | 423 | 1.240 |
Why?
| | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2023 | 26 | 1.240 |
Why?
| | Repressor Proteins | 5 | 2022 | 427 | 1.230 |
Why?
| | Thrombocytopenia | 4 | 2020 | 200 | 1.200 |
Why?
| | Genetic Testing | 4 | 2024 | 460 | 1.140 |
Why?
| | Neoplasms | 11 | 2025 | 2671 | 1.130 |
Why?
| | Cell Cycle Proteins | 4 | 2017 | 617 | 1.090 |
Why?
| | Protein-Tyrosine Kinases | 3 | 2017 | 434 | 1.060 |
Why?
| | Burkitt Lymphoma | 2 | 2023 | 60 | 0.980 |
Why?
| | Nuclear Proteins | 3 | 2017 | 712 | 0.950 |
Why?
| | Hematopoietic Stem Cells | 6 | 2021 | 406 | 0.790 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 2017 | 1692 | 0.780 |
Why?
| | Hypoxanthine Phosphoribosyltransferase | 2 | 2013 | 25 | 0.700 |
Why?
| | Tumor Microenvironment | 7 | 2025 | 674 | 0.690 |
Why?
| | Myelodysplastic Syndromes | 2 | 2024 | 135 | 0.680 |
Why?
| | Genetic Counseling | 1 | 2020 | 77 | 0.660 |
Why?
| | RNA, Small Interfering | 6 | 2018 | 622 | 0.660 |
Why?
| | Cytarabine | 3 | 2017 | 61 | 0.630 |
Why?
| | Gene Knockdown Techniques | 4 | 2019 | 327 | 0.610 |
Why?
| | Calcineurin | 1 | 2019 | 108 | 0.590 |
Why?
| | Pyrimidinones | 5 | 2017 | 113 | 0.590 |
Why?
| | Antimetabolites, Antineoplastic | 3 | 2013 | 94 | 0.580 |
Why?
| | Hematologic Diseases | 2 | 2015 | 62 | 0.580 |
Why?
| | Cell Line, Tumor | 13 | 2022 | 3412 | 0.570 |
Why?
| | Apoptosis | 9 | 2022 | 2553 | 0.560 |
Why?
| | Mice | 22 | 2025 | 17787 | 0.560 |
Why?
| | CDC2 Protein Kinase | 1 | 2017 | 31 | 0.560 |
Why?
| | Cyclin-Dependent Kinase 2 | 1 | 2017 | 39 | 0.550 |
Why?
| | Neoplasm Proteins | 3 | 2021 | 434 | 0.550 |
Why?
| | Li-Fraumeni Syndrome | 1 | 2017 | 14 | 0.540 |
Why?
| | Recombinational DNA Repair | 1 | 2017 | 16 | 0.540 |
Why?
| | DNA Repair | 2 | 2017 | 231 | 0.540 |
Why?
| | Thioguanine | 3 | 2013 | 19 | 0.530 |
Why?
| | Phthalazines | 1 | 2017 | 45 | 0.530 |
Why?
| | Antineoplastic Agents | 7 | 2022 | 2129 | 0.520 |
Why?
| | Early Detection of Cancer | 4 | 2025 | 447 | 0.520 |
Why?
| | Child | 25 | 2025 | 21935 | 0.500 |
Why?
| | Hematopoietic Stem Cell Transplantation | 5 | 2024 | 622 | 0.500 |
Why?
| | Humans | 64 | 2025 | 137585 | 0.480 |
Why?
| | Piperazines | 2 | 2017 | 350 | 0.480 |
Why?
| | Cytokines | 6 | 2023 | 2085 | 0.470 |
Why?
| | Tumor Suppressor Protein p53 | 5 | 2017 | 528 | 0.460 |
Why?
| | Fusion Proteins, bcr-abl | 2 | 2014 | 69 | 0.450 |
Why?
| | Calcineurin Inhibitors | 1 | 2014 | 72 | 0.430 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2014 | 122 | 0.410 |
Why?
| | Animals | 22 | 2025 | 36940 | 0.400 |
Why?
| | Transduction, Genetic | 1 | 2013 | 127 | 0.390 |
Why?
| | Bone Marrow | 3 | 2022 | 286 | 0.390 |
Why?
| | Drug Synergism | 4 | 2015 | 382 | 0.380 |
Why?
| | Xenograft Model Antitumor Assays | 7 | 2018 | 872 | 0.380 |
Why?
| | Drug Resistance | 2 | 2013 | 169 | 0.370 |
Why?
| | DNA-Binding Proteins | 3 | 2024 | 1502 | 0.360 |
Why?
| | Leukemia, Experimental | 1 | 2011 | 27 | 0.350 |
Why?
| | Lymphoproliferative Disorders | 2 | 2008 | 57 | 0.350 |
Why?
| | Myeloproliferative Disorders | 1 | 2011 | 27 | 0.350 |
Why?
| | Drug Resistance, Neoplasm | 4 | 2017 | 801 | 0.340 |
Why?
| | Genomics | 3 | 2022 | 795 | 0.310 |
Why?
| | Neoplastic Stem Cells | 2 | 2025 | 399 | 0.300 |
Why?
| | Charcot-Marie-Tooth Disease | 1 | 2009 | 21 | 0.300 |
Why?
| | Vincristine | 1 | 2009 | 116 | 0.290 |
Why?
| | Influenza Vaccines | 2 | 2004 | 539 | 0.290 |
Why?
| | DNA Damage | 4 | 2023 | 420 | 0.280 |
Why?
| | Peripheral Nervous System Diseases | 1 | 2009 | 128 | 0.280 |
Why?
| | Triazoles | 1 | 2009 | 147 | 0.280 |
Why?
| | Flow Cytometry | 4 | 2019 | 1178 | 0.270 |
Why?
| | Purines | 1 | 2008 | 176 | 0.270 |
Why?
| | Cell Separation | 1 | 2008 | 318 | 0.270 |
Why?
| | Immunity, Innate | 2 | 2025 | 828 | 0.250 |
Why?
| | Leukemia, Myelomonocytic, Juvenile | 1 | 2025 | 4 | 0.240 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 2025 | 23 | 0.240 |
Why?
| | Medical Oncology | 3 | 2023 | 289 | 0.240 |
Why?
| | Organ Transplantation | 1 | 2008 | 250 | 0.230 |
Why?
| | Single-Cell Analysis | 2 | 2025 | 313 | 0.230 |
Why?
| | Immune Evasion | 1 | 2025 | 58 | 0.230 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2023 | 900 | 0.230 |
Why?
| | Mutation | 6 | 2025 | 3958 | 0.230 |
Why?
| | Biomarkers, Tumor | 1 | 2012 | 1276 | 0.230 |
Why?
| | Female | 21 | 2024 | 73304 | 0.210 |
Why?
| | Influenza B virus | 1 | 2004 | 44 | 0.210 |
Why?
| | Gastrointestinal Neoplasms | 1 | 2024 | 77 | 0.210 |
Why?
| | Syndrome | 2 | 2023 | 358 | 0.210 |
Why?
| | Sialic Acid Binding Immunoglobulin-like Lectins | 1 | 2023 | 9 | 0.210 |
Why?
| | Y-Box-Binding Protein 1 | 1 | 2023 | 6 | 0.210 |
Why?
| | Mice, Inbred C57BL | 5 | 2025 | 5757 | 0.210 |
Why?
| | Amides | 1 | 2023 | 93 | 0.200 |
Why?
| | Interferon-gamma | 2 | 2017 | 789 | 0.200 |
Why?
| | Sulfones | 1 | 2023 | 110 | 0.200 |
Why?
| | Immunoglobulins | 1 | 2023 | 171 | 0.200 |
Why?
| | Thrombopoiesis | 1 | 2022 | 8 | 0.200 |
Why?
| | Brain Diseases, Metabolic, Inborn | 1 | 2022 | 4 | 0.200 |
Why?
| | Triple Negative Breast Neoplasms | 2 | 2016 | 202 | 0.190 |
Why?
| | Adaptive Immunity | 1 | 2023 | 165 | 0.190 |
Why?
| | Germ Cells | 1 | 2022 | 64 | 0.190 |
Why?
| | Galectins | 1 | 2022 | 24 | 0.190 |
Why?
| | Thrombopoietin | 1 | 2021 | 5 | 0.180 |
Why?
| | Urogenital Abnormalities | 1 | 2022 | 64 | 0.180 |
Why?
| | Immunization | 1 | 2004 | 411 | 0.180 |
Why?
| | Cerebellar Neoplasms | 1 | 2023 | 152 | 0.180 |
Why?
| | Neural Stem Cells | 1 | 2023 | 156 | 0.180 |
Why?
| | Metabolic Diseases | 1 | 2022 | 108 | 0.180 |
Why?
| | Genes, p53 | 2 | 2012 | 72 | 0.180 |
Why?
| | Medulloblastoma | 1 | 2023 | 193 | 0.180 |
Why?
| | Nuclear Receptor Co-Repressor 2 | 1 | 2020 | 15 | 0.170 |
Why?
| | Bone Marrow Diseases | 1 | 2020 | 19 | 0.170 |
Why?
| | Interferon Regulatory Factors | 1 | 2020 | 39 | 0.170 |
Why?
| | Mobile Applications | 1 | 2023 | 183 | 0.170 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2021 | 81 | 0.170 |
Why?
| | Polymers | 2 | 2023 | 490 | 0.160 |
Why?
| | Stem Cell Niche | 1 | 2020 | 54 | 0.160 |
Why?
| | Core Binding Factor Alpha 2 Subunit | 1 | 2019 | 31 | 0.160 |
Why?
| | Antibodies, Bispecific | 1 | 2020 | 55 | 0.160 |
Why?
| | Practice Guidelines as Topic | 2 | 2024 | 1587 | 0.160 |
Why?
| | Leukemia, Myeloid | 1 | 2019 | 45 | 0.160 |
Why?
| | Phenotype | 4 | 2023 | 3196 | 0.160 |
Why?
| | Cell Line | 5 | 2021 | 2847 | 0.160 |
Why?
| | Genotype | 2 | 2022 | 1916 | 0.150 |
Why?
| | Bone Marrow Cells | 1 | 2020 | 316 | 0.150 |
Why?
| | Tumor Escape | 1 | 2019 | 42 | 0.150 |
Why?
| | Up-Regulation | 3 | 2018 | 843 | 0.150 |
Why?
| | Dendritic Cells | 1 | 2022 | 483 | 0.150 |
Why?
| | Cardiomyopathy, Dilated | 1 | 2022 | 385 | 0.150 |
Why?
| | PAX2 Transcription Factor | 1 | 2018 | 8 | 0.150 |
Why?
| | Osmoregulation | 1 | 2018 | 4 | 0.150 |
Why?
| | PAX5 Transcription Factor | 1 | 2018 | 14 | 0.150 |
Why?
| | Histone Deacetylases | 1 | 2020 | 215 | 0.150 |
Why?
| | NADPH Oxidases | 2 | 2017 | 113 | 0.150 |
Why?
| | Lesch-Nyhan Syndrome | 1 | 2018 | 3 | 0.150 |
Why?
| | Anemia, Macrocytic | 1 | 2018 | 4 | 0.150 |
Why?
| | Personal Satisfaction | 1 | 2020 | 207 | 0.150 |
Why?
| | Carcinogenesis | 1 | 2020 | 217 | 0.150 |
Why?
| | Membrane Proteins | 2 | 2023 | 1164 | 0.150 |
Why?
| | Interferon-alpha | 1 | 2019 | 198 | 0.150 |
Why?
| | Cardiomyopathies | 1 | 2022 | 350 | 0.150 |
Why?
| | Disease Management | 2 | 2019 | 628 | 0.140 |
Why?
| | Disease Progression | 2 | 2019 | 2757 | 0.140 |
Why?
| | DNA Repair-Deficiency Disorders | 1 | 2017 | 4 | 0.140 |
Why?
| | Counseling | 1 | 2020 | 391 | 0.140 |
Why?
| | Brain Neoplasms | 2 | 2024 | 1238 | 0.130 |
Why?
| | Protein Kinase Inhibitors | 2 | 2014 | 916 | 0.130 |
Why?
| | Anion Transport Proteins | 1 | 2017 | 9 | 0.130 |
Why?
| | Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2017 | 30 | 0.130 |
Why?
| | TNF-Related Apoptosis-Inducing Ligand | 1 | 2017 | 52 | 0.130 |
Why?
| | Hepatoblastoma | 1 | 2017 | 46 | 0.130 |
Why?
| | Autoimmune Diseases | 1 | 2021 | 460 | 0.130 |
Why?
| | Interleukin-1 | 1 | 2021 | 965 | 0.130 |
Why?
| | Cell Proliferation | 3 | 2023 | 2475 | 0.130 |
Why?
| | Child, Preschool | 7 | 2025 | 11074 | 0.130 |
Why?
| | Family | 1 | 2021 | 671 | 0.130 |
Why?
| | Infant | 5 | 2021 | 9465 | 0.120 |
Why?
| | Wilms Tumor | 1 | 2017 | 86 | 0.120 |
Why?
| | Calcitriol | 1 | 2016 | 58 | 0.120 |
Why?
| | Adult | 10 | 2024 | 37929 | 0.120 |
Why?
| | RNA | 1 | 2022 | 921 | 0.120 |
Why?
| | Prednisolone | 1 | 2015 | 83 | 0.120 |
Why?
| | T-Lymphocytes | 2 | 2021 | 1996 | 0.120 |
Why?
| | Immunologic Factors | 3 | 2023 | 236 | 0.120 |
Why?
| | Lymphocyte Activation | 1 | 2019 | 1142 | 0.120 |
Why?
| | Cells, Cultured | 4 | 2011 | 4193 | 0.110 |
Why?
| | Protein Tyrosine Phosphatases | 1 | 2016 | 172 | 0.110 |
Why?
| | Pediatrics | 1 | 2003 | 1101 | 0.110 |
Why?
| | Hemorrhage | 1 | 2019 | 722 | 0.110 |
Why?
| | Male | 14 | 2024 | 67762 | 0.110 |
Why?
| | Signal Transduction | 4 | 2025 | 5079 | 0.110 |
Why?
| | Genetic Variation | 1 | 2019 | 991 | 0.110 |
Why?
| | Oligonucleotide Array Sequence Analysis | 2 | 2017 | 767 | 0.110 |
Why?
| | Telemedicine | 1 | 2023 | 862 | 0.110 |
Why?
| | Dasatinib | 1 | 2014 | 54 | 0.110 |
Why?
| | S Phase | 2 | 2012 | 77 | 0.110 |
Why?
| | Practice Patterns, Physicians' | 1 | 2003 | 1313 | 0.110 |
Why?
| | Pyridones | 1 | 2015 | 168 | 0.110 |
Why?
| | Thiazoles | 1 | 2014 | 123 | 0.110 |
Why?
| | Blotting, Western | 2 | 2017 | 1226 | 0.110 |
Why?
| | MAP Kinase Signaling System | 1 | 2015 | 320 | 0.100 |
Why?
| | Cell Cycle Checkpoints | 1 | 2013 | 98 | 0.100 |
Why?
| | Cyclosporine | 1 | 2014 | 268 | 0.100 |
Why?
| | Antigens, CD34 | 1 | 2013 | 88 | 0.100 |
Why?
| | Down Syndrome | 1 | 2019 | 496 | 0.100 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2019 | 1091 | 0.100 |
Why?
| | Membrane Glycoproteins | 1 | 2015 | 500 | 0.100 |
Why?
| | Umbilical Cord | 1 | 2013 | 85 | 0.100 |
Why?
| | Vitamin D | 1 | 2016 | 397 | 0.100 |
Why?
| | Tankyrases | 1 | 2012 | 15 | 0.100 |
Why?
| | STAT3 Transcription Factor | 1 | 2014 | 206 | 0.100 |
Why?
| | Parents | 1 | 2020 | 1347 | 0.090 |
Why?
| | Drug Discovery | 1 | 2013 | 142 | 0.090 |
Why?
| | Myeloid Cells | 1 | 2013 | 148 | 0.090 |
Why?
| | Neutrophils | 1 | 2017 | 1238 | 0.090 |
Why?
| | Proto-Oncogene Proteins c-met | 1 | 2012 | 75 | 0.090 |
Why?
| | Gene Expression Profiling | 2 | 2025 | 1774 | 0.090 |
Why?
| | Cell Differentiation | 2 | 2018 | 1991 | 0.090 |
Why?
| | Wnt Proteins | 1 | 2012 | 133 | 0.090 |
Why?
| | Autophagy | 1 | 2014 | 284 | 0.090 |
Why?
| | Inflammation | 1 | 2022 | 2837 | 0.090 |
Why?
| | Gene Knock-In Techniques | 1 | 2011 | 56 | 0.090 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2012 | 346 | 0.090 |
Why?
| | Lymphocytes | 1 | 2013 | 397 | 0.090 |
Why?
| | Kidney | 1 | 2018 | 1468 | 0.080 |
Why?
| | Aging | 1 | 2021 | 1864 | 0.080 |
Why?
| | Recurrence | 2 | 2023 | 1060 | 0.080 |
Why?
| | Tumor Cells, Cultured | 1 | 2012 | 955 | 0.080 |
Why?
| | Tumor Suppressor Proteins | 1 | 2012 | 327 | 0.080 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2012 | 976 | 0.080 |
Why?
| | Cyclophilin A | 1 | 2009 | 26 | 0.080 |
Why?
| | Basigin | 1 | 2009 | 25 | 0.080 |
Why?
| | Genome, Human | 1 | 2012 | 425 | 0.080 |
Why?
| | Cell Cycle | 2 | 2012 | 601 | 0.080 |
Why?
| | Infant, Newborn | 1 | 2021 | 6079 | 0.080 |
Why?
| | Voriconazole | 1 | 2009 | 20 | 0.080 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2011 | 215 | 0.080 |
Why?
| | Adolescent | 6 | 2025 | 21513 | 0.080 |
Why?
| | ErbB Receptors | 1 | 2012 | 614 | 0.080 |
Why?
| | Proto-Oncogene Proteins c-bcl-6 | 1 | 2008 | 8 | 0.080 |
Why?
| | Protein Transport | 2 | 2020 | 445 | 0.070 |
Why?
| | Obesity | 1 | 2022 | 2992 | 0.070 |
Why?
| | Lentivirus | 1 | 2008 | 56 | 0.070 |
Why?
| | Pregnancy | 1 | 2021 | 6763 | 0.070 |
Why?
| | Clinical Trials as Topic | 1 | 2013 | 1050 | 0.070 |
Why?
| | Protein Folding | 1 | 2009 | 280 | 0.070 |
Why?
| | Genetic Vectors | 1 | 2008 | 319 | 0.070 |
Why?
| | Immunotherapy | 2 | 2021 | 641 | 0.060 |
Why?
| | Calgranulin B | 1 | 2025 | 10 | 0.060 |
Why?
| | Calgranulin A | 1 | 2025 | 11 | 0.060 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2007 | 98 | 0.060 |
Why?
| | Genetic Association Studies | 2 | 2019 | 377 | 0.060 |
Why?
| | Hodgkin Disease | 1 | 2007 | 138 | 0.060 |
Why?
| | Gene Expression Regulation, Leukemic | 1 | 2025 | 56 | 0.060 |
Why?
| | Peutz-Jeghers Syndrome | 1 | 2024 | 10 | 0.060 |
Why?
| | Adenomatous Polyposis Coli | 1 | 2024 | 39 | 0.060 |
Why?
| | MutL Protein Homolog 1 | 1 | 2024 | 12 | 0.060 |
Why?
| | Neoplasm, Residual | 1 | 2025 | 133 | 0.060 |
Why?
| | Cohort Studies | 2 | 2020 | 5742 | 0.060 |
Why?
| | MutS Homolog 2 Protein | 1 | 2024 | 15 | 0.060 |
Why?
| | HEK293 Cells | 2 | 2018 | 730 | 0.050 |
Why?
| | Hemagglutination Inhibition Tests | 1 | 2004 | 38 | 0.050 |
Why?
| | DNA Mismatch Repair | 1 | 2024 | 49 | 0.050 |
Why?
| | B-Lymphocytes | 2 | 2020 | 847 | 0.050 |
Why?
| | Serologic Tests | 1 | 2004 | 54 | 0.050 |
Why?
| | Longitudinal Studies | 2 | 2024 | 2844 | 0.050 |
Why?
| | DNA Replication | 1 | 2005 | 238 | 0.050 |
Why?
| | RNA, Messenger | 1 | 2012 | 2833 | 0.050 |
Why?
| | Unrelated Donors | 1 | 2023 | 39 | 0.050 |
Why?
| | Survival Rate | 1 | 2008 | 1972 | 0.050 |
Why?
| | Mice, Inbred BALB C | 2 | 2021 | 1272 | 0.050 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2005 | 327 | 0.050 |
Why?
| | Antigens, Viral | 1 | 2004 | 178 | 0.050 |
Why?
| | Remission Induction | 1 | 2023 | 288 | 0.050 |
Why?
| | Morbidity | 1 | 2023 | 324 | 0.050 |
Why?
| | Transplantation, Homologous | 1 | 2023 | 416 | 0.050 |
Why?
| | Hedgehog Proteins | 1 | 2023 | 195 | 0.050 |
Why?
| | Receptors, Thrombopoietin | 1 | 2021 | 6 | 0.050 |
Why?
| | Rare Diseases | 1 | 2022 | 104 | 0.050 |
Why?
| | Receptors, Cytokine | 1 | 2021 | 36 | 0.050 |
Why?
| | Mice, Nude | 2 | 2014 | 698 | 0.040 |
Why?
| | Disease Susceptibility | 1 | 2023 | 347 | 0.040 |
Why?
| | Mitochondrial Proteins | 1 | 2023 | 257 | 0.040 |
Why?
| | Middle Aged | 3 | 2019 | 33479 | 0.040 |
Why?
| | Antigens, Neoplasm | 1 | 2023 | 319 | 0.040 |
Why?
| | Sequence Analysis, RNA | 1 | 2023 | 452 | 0.040 |
Why?
| | Megakaryocytes | 1 | 2020 | 34 | 0.040 |
Why?
| | Acute Disease | 1 | 2023 | 1007 | 0.040 |
Why?
| | Prospective Studies | 2 | 2023 | 7604 | 0.040 |
Why?
| | Disease Models, Animal | 1 | 2011 | 4295 | 0.040 |
Why?
| | CD3 Complex | 1 | 2020 | 106 | 0.040 |
Why?
| | Young Adult | 3 | 2024 | 13209 | 0.040 |
Why?
| | Prognosis | 1 | 2008 | 4030 | 0.040 |
Why?
| | Antigens, CD19 | 1 | 2020 | 123 | 0.040 |
Why?
| | Antibodies, Viral | 1 | 2004 | 625 | 0.040 |
Why?
| | Treatment Outcome | 1 | 2014 | 10811 | 0.040 |
Why?
| | Penetrance | 1 | 2019 | 28 | 0.040 |
Why?
| | Protein Binding | 2 | 2020 | 2224 | 0.040 |
Why?
| | Ligands | 1 | 2021 | 664 | 0.040 |
Why?
| | Carrier Proteins | 1 | 2023 | 771 | 0.040 |
Why?
| | Liver Transplantation | 1 | 2007 | 871 | 0.040 |
Why?
| | Hypertonic Solutions | 1 | 2018 | 7 | 0.040 |
Why?
| | Lung Neoplasms | 1 | 2012 | 2526 | 0.040 |
Why?
| | Transcriptome | 1 | 2025 | 971 | 0.040 |
Why?
| | DNA | 1 | 2005 | 1459 | 0.040 |
Why?
| | Primary Cell Culture | 1 | 2018 | 171 | 0.040 |
Why?
| | Coculture Techniques | 1 | 2018 | 239 | 0.040 |
Why?
| | Proto-Oncogene Proteins | 1 | 2021 | 648 | 0.040 |
Why?
| | Bloom Syndrome | 1 | 2017 | 3 | 0.030 |
Why?
| | Polyethylene Glycols | 1 | 2023 | 641 | 0.030 |
Why?
| | Ataxia Telangiectasia | 1 | 2017 | 20 | 0.030 |
Why?
| | Fanconi Anemia | 1 | 2017 | 11 | 0.030 |
Why?
| | Xeroderma Pigmentosum | 1 | 2017 | 8 | 0.030 |
Why?
| | Muramidase | 1 | 2017 | 78 | 0.030 |
Why?
| | Chemotaxis, Leukocyte | 1 | 2017 | 136 | 0.030 |
Why?
| | Peroxidase | 1 | 2017 | 175 | 0.030 |
Why?
| | Incidence | 1 | 2024 | 2804 | 0.030 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2023 | 1079 | 0.030 |
Why?
| | Clinical Decision-Making | 1 | 2019 | 322 | 0.030 |
Why?
| | Europe | 1 | 2017 | 414 | 0.030 |
Why?
| | Colorectal Neoplasms | 1 | 2024 | 806 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2004 | 3556 | 0.030 |
Why?
| | MAP Kinase Kinase 4 | 1 | 2015 | 29 | 0.030 |
Why?
| | MAP Kinase Kinase 2 | 1 | 2015 | 28 | 0.030 |
Why?
| | NADPH Oxidase 2 | 1 | 2015 | 39 | 0.030 |
Why?
| | Oncogenes | 1 | 2016 | 116 | 0.030 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 2016 | 194 | 0.030 |
Why?
| | Mice, Transgenic | 1 | 2021 | 2167 | 0.030 |
Why?
| | Phagocytosis | 1 | 2017 | 380 | 0.030 |
Why?
| | Erythrocytes, Abnormal | 1 | 2015 | 12 | 0.030 |
Why?
| | Vaccination | 1 | 2004 | 1381 | 0.030 |
Why?
| | Risk Assessment | 1 | 2024 | 3457 | 0.030 |
Why?
| | Beclin-1 | 1 | 2014 | 11 | 0.030 |
Why?
| | Autophagy-Related Protein 7 | 1 | 2014 | 13 | 0.030 |
Why?
| | Ubiquitin-Activating Enzymes | 1 | 2014 | 17 | 0.030 |
Why?
| | Mass Screening | 1 | 2022 | 1287 | 0.030 |
Why?
| | Chloroquine | 1 | 2014 | 54 | 0.030 |
Why?
| | DNA Mutational Analysis | 1 | 2015 | 399 | 0.030 |
Why?
| | Exome | 1 | 2015 | 231 | 0.030 |
Why?
| | Pedigree | 1 | 2015 | 514 | 0.030 |
Why?
| | Cell Survival | 1 | 2017 | 1120 | 0.030 |
Why?
| | Gene Expression Regulation | 2 | 2017 | 2607 | 0.030 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2014 | 188 | 0.030 |
Why?
| | Mutation, Missense | 1 | 2015 | 341 | 0.030 |
Why?
| | United States | 2 | 2017 | 14841 | 0.020 |
Why?
| | Tumor Burden | 1 | 2014 | 309 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2024 | 5472 | 0.020 |
Why?
| | Genes, Synthetic | 1 | 2012 | 15 | 0.020 |
Why?
| | Genes, Lethal | 1 | 2012 | 30 | 0.020 |
Why?
| | Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2012 | 19 | 0.020 |
Why?
| | Ataxia Telangiectasia Mutated Proteins | 1 | 2012 | 66 | 0.020 |
Why?
| | RNA Interference | 1 | 2014 | 469 | 0.020 |
Why?
| | Doxorubicin | 1 | 2014 | 362 | 0.020 |
Why?
| | Age Factors | 1 | 2019 | 3295 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2019 | 3284 | 0.020 |
Why?
| | Protein Processing, Post-Translational | 1 | 2014 | 465 | 0.020 |
Why?
| | Imidazoles | 1 | 2012 | 238 | 0.020 |
Why?
| | Mice, Knockout | 2 | 2010 | 3015 | 0.020 |
Why?
| | Quinazolines | 1 | 2012 | 251 | 0.020 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2017 | 1396 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2003 | 5778 | 0.020 |
Why?
| | Radiation, Ionizing | 1 | 2010 | 80 | 0.020 |
Why?
| | Phosphorylation | 1 | 2014 | 1759 | 0.020 |
Why?
| | Syndecan-1 | 1 | 2009 | 38 | 0.020 |
Why?
| | Bone Marrow Transplantation | 1 | 2010 | 286 | 0.020 |
Why?
| | Genome-Wide Association Study | 1 | 2015 | 1431 | 0.020 |
Why?
| | Lymphoma | 1 | 2010 | 208 | 0.020 |
Why?
| | Catalysis | 1 | 2009 | 307 | 0.020 |
Why?
| | Protein Structure, Secondary | 1 | 2009 | 374 | 0.020 |
Why?
| | Protein Isoforms | 1 | 2009 | 404 | 0.020 |
Why?
| | Reed-Sternberg Cells | 1 | 2007 | 3 | 0.020 |
Why?
| | Adenoids | 1 | 2007 | 12 | 0.020 |
Why?
| | Recombinant Fusion Proteins | 1 | 2010 | 665 | 0.020 |
Why?
| | Palatine Tonsil | 1 | 2007 | 48 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2009 | 861 | 0.020 |
Why?
| | E2F2 Transcription Factor | 1 | 2005 | 15 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2009 | 1353 | 0.020 |
Why?
| | Hydroxyurea | 1 | 2005 | 35 | 0.020 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2007 | 317 | 0.020 |
Why?
| | E2F1 Transcription Factor | 1 | 2005 | 64 | 0.020 |
Why?
| | Precancerous Conditions | 1 | 2007 | 169 | 0.010 |
Why?
| | Immunocompromised Host | 1 | 2007 | 202 | 0.010 |
Why?
| | Biliary Atresia | 1 | 2007 | 163 | 0.010 |
Why?
| | Lymph Nodes | 1 | 2007 | 491 | 0.010 |
Why?
| | Models, Molecular | 1 | 2009 | 1570 | 0.010 |
Why?
| | Polymerase Chain Reaction | 1 | 2007 | 1062 | 0.010 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2012 | 1081 | 0.010 |
Why?
| | RNA, Viral | 1 | 2007 | 656 | 0.010 |
Why?
| | Risk Factors | 1 | 2017 | 10388 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2007 | 1738 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2005 | 2900 | 0.010 |
Why?
| | Biomarkers | 1 | 2010 | 4149 | 0.010 |
Why?
|
|
Porter's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|